Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
67%(6 trials)

Phase Distribution

Ph phase_1
4
44%
Ph phase_2
5
56%

Phase Distribution

4

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
5(55.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (44.4%)
Phase 25 (55.6%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

NCT03239145
completedphase_1

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

NCT01555268
completedphase_2

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

NCT01609790
completedphase_2

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

NCT01664182
completedphase_2

AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

NCT00853372
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03239145Phase 1

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Completed
NCT01555268Phase 1

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Completed
NCT01609790Phase 2

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Completed
NCT01664182Phase 2

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Completed
NCT00853372Phase 2

AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

Completed
NCT01210222Phase 2

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Completed
NCT01538095Phase 1

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors

Completed
NCT01623869Phase 2

Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery

Completed
NCT01548482Phase 1

Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9